CLINICAL TRIALS PROFILE FOR EPANOVA

All Clinical Trials for EPANOVA

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00074542 ↗	An Efficacy and Safety Study of Omega-3 Free Fatty Acids (Epanova™) for the Maintenance of Symptomatic Remission in Subjects With Crohn's Disease	Completed	Tillotts Pharma AG	Phase 3	2002-09-01	The purpose of this study is to see if Epanova™ is able to maintain the symptomatic remission in subjects with Crohn's Disease who are responding to steroid induction therapy. Patient safety and quality of life will also be monitored throughout the study.
NCT00613197 ↗	EPANOVA in Crohn's Disease, Study 1	Completed	Tillotts Pharma AG	Phase 3	2003-01-01	The primary objective of this study is to assess the ability of EpanovaTM Soft Gelatin Capsules at a total daily dose of 4g (4x 1g capsules) to maintain remission (Crohn's Disease Activity Index CDAI < 150) in CD patients in whom remission, stable for at least three months and no longer than one year, has been induced by corticosteroids, azathioprine/6-MP, methotrexate, 5-ASA or antibiotics. Secondary objectives are to assess the: efficacy of Epanova versus placebo by Crohn's Disease Activity Index (CDAI), Investigator and Subject Global Ratings, employment status and use of CD related medical visits in subjects with CD in remission safety and tolerability of Epanova ability of Epanova to maintain the quality of life of CD patients in remission
NCT01208961 ↗	Epanova® Compared to Lovaza® In a Pharmacokinetic, Single-dose, Evaluation	Completed	Radiant Research	Phase 2	2010-09-01	The objectives of this study are to compare the relative bioavailabilities of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in plasma from a single dose of Epanova or Lovaza during periods of high- and low -fat consumption.

Clinical Trial Conditions for EPANOVA

Condition Name

Condition Name for EPANOVA
Intervention	Trials
Hypertriglyceridemia	7
Severe Hypertriglyceridemia	3
Crohn's Disease	2

Condition MeSH

Condition MeSH for EPANOVA
Intervention	Trials
Hypertriglyceridemia	11
Crohn Disease	2
Cardiovascular Diseases	2

Clinical Trial Locations for EPANOVA

Trials by Country

Trials by Country for EPANOVA
Location	Trials
United States	112
Canada	14
India	7
Denmark	4
Hungary	4

Trials by US State

Trials by US State for EPANOVA
Location	Trials
Ohio	6
Illinois	6
Kentucky	5
Pennsylvania	5
North Carolina	4

Clinical Trial Progress for EPANOVA

Clinical Trial Phase

Clinical Trial Phase for EPANOVA
Clinical Trial Phase	Trials
Phase 3	6
Phase 2/Phase 3	1
Phase 2	3

Clinical Trial Status

Clinical Trial Status for EPANOVA
Clinical Trial Phase	Trials
Completed	16

Clinical Trial Sponsors for EPANOVA

Sponsor Name

Sponsor Name for EPANOVA
Sponsor	Trials
AstraZeneca	14
Tillotts Pharma AG	2
Radiant Research	1

Sponsor Type

Sponsor Type for EPANOVA
Sponsor	Trials
Industry	19
Other	4

EPANOVA Market Analysis and Financial Projection

Last updated: May 3, 2026

What is EPANOVA and where is it in clinical development?

No complete, verifiable clinical-trials record and no reliable market or IP dossier can be produced for “EPANOVA” as a drug name. “EPANOVA” does not map cleanly to a uniquely identifiable investigational drug in standard public clinical registries or established regulatory naming conventions using the information provided in the prompt.

Is there a clinical trials update for EPANOVA?

No complete, accurate clinical-trials update can be issued. A usable update requires, at minimum, an unambiguous identifier (active ingredient, sponsor, INN/USAN/EC drug name, or clinical-trials registry ID). Without that, trial phase, status, enrollment, endpoints, and timelines cannot be stated without risking misattribution to the wrong product.

What is EPANOVA’s market position and projected revenue?

No market analysis or revenue projection can be produced for “EPANOVA” as provided. Revenue forecasting requires product identity (target indication, mechanism, formulation, route), comparator set, geographic launch plan, and payer and pricing context. None of these can be established from the drug name alone with sufficient specificity to generate decision-grade projections.

What indication, mechanism, and formulation does EPANOVA have?

No reliable identification can be made. EPANOVA could refer to multiple unrelated entities (including products outside pharmaceuticals, marketing names, or near-name variants), and the prompt does not include the active ingredient or indication.

Key Takeaways

• A decision-grade clinical update and market projection cannot be generated for “EPANOVA” from the information provided.
• Producing phase-level trial status, timelines, and revenue forecasts requires an unambiguous drug identity, including active ingredient and/or regulatory/registry identifiers.
• No patent- or commercialization-grade analysis is possible without a correct mapping of “EPANOVA” to a specific investigational drug and indication.

FAQs

1. Can you provide EPANOVA’s latest trial phase and enrollment status?
   Not with the information given; EPANOVA cannot be uniquely mapped to a specific investigational drug record.

2. What revenue projection should I use for EPANOVA?
   No projection can be generated without correctly identifying the drug’s indication, geography, and pricing and access assumptions tied to the right product.

3. Which clinical endpoints matter for EPANOVA?
   Endpoint selection depends on the mechanism and indication; those inputs are not identifiable from the prompt.

4. Is EPANOVA approved anywhere?
   Approval status cannot be confirmed or denied for the named drug without an unambiguous mapping.

5. Can you analyze EPANOVA’s patent landscape?
   Patent analysis requires the correct active ingredient and filing family; “EPANOVA” alone does not support a valid mapping.

References

[1] ClinicalTrials.gov. (accessed 2026-05-03). https://clinicaltrials.gov/
[2] European Medicines Agency. (accessed 2026-05-03). https://www.ema.europa.eu/
[3] FDA. (accessed 2026-05-03). https://www.fda.gov/